Press Releases

News & Updates

The latest announcements and insights from BigStocks.

October 1, 2026

Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

Cosmos Health's portfolio of more than 15 proprietary brands and product lines and 10 branded generics is now sold in more than 40 countries across Europe, the Middle East, North America and Asia, addressing product and service markets estimated at approximately $946 billion in 2025 and projected to reach approximately $1.76 trillion by 2033.

October 1, 2026

IQSTEL Announces Edison Initiation of Coverage with $6 Per Share Valuation, Forecasting $653 Million in 2027 Revenue and Positive Free Cash Flow

IQSTEL announced that Edison Investment Research has initiated coverage with a $6 per share valuation assessment, forecasting $653 million in 2027 revenue, $12.5 million in adjusted EBITDA and approximately $7 million in free cash flow as Ultranet and higher-margin digital services support the Company's transition from revenue scale toward stronger profitability and cash generation.

September 29, 2026

Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue

Cosmos Health's wholly owned pharmaceutical distribution subsidiary CosmoFarm has reached an annualized revenue run-rate above $60 million following record Q2 2026 revenue of more than $15 million, representing approximately 4.3x growth since fiscal 2017, while robotics, automation and AI-enabled infrastructure are being expanded to support annualized revenue above $100 million.

September 28, 2026

Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Record 32.7 Million-Unit Production Pipeline

Cosmos Health's contract manufacturing division has surpassed $20 million in implied revenue and $18 million in implied gross profit across a record 32.7 million-unit production pipeline, with gross margins above 90% and agreements averaging approximately four years as Cana Laboratories scales toward more than $10 million in recurring annual gross profit at full capacity.

September 24, 2026

Digital Brands Group Delivers 221% Revenue Growth While Cutting Marketing Spend by 78%; AVO Achieves 3.65x ROAS

Digital Brands Group’s collegiate licensing brand AVO delivered 221% year-over-year revenue growth while reducing digital marketing spend by 78% from August 1 through September 11, 2026, achieving a 3.65x ROAS as weekly net revenue among universities launched in 2026 increased 442% from Week 1 to Week 6.

September 15, 2026

Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June

Cosmos Health has secured new five-year contract manufacturing agreements with Target Pharma for approximately 5.2 million units, lifting Cana Laboratories' cumulative orderbook above 32.7 million units, up 31% since June 2026, as the division expands across 11 therapeutic categories and targets more than $10 million in recurring annual profit at full capacity.

September 14, 2026

Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market

Cosmos Health has engaged Prime Ledger to structure an asset-specific, non-dilutive tokenized financing backed by the intellectual property of CCX0722, its ingestible hydrogel-based weight-management medical device, positioning the Company at the intersection of a projected $562.2 billion weight-management market and a rapidly expanding tokenized real-world-asset market.

September 11, 2026

Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units

Cosmos Health has secured a new five-year contract manufacturing agreement through Cana Laboratories for approximately 2.5 million units of ROSARTIA, expanding its cardiovascular pharmaceutical manufacturing presence and increasing Cana's cumulative contract manufacturing orderbook to more than 27.5 million units.

September 10, 2026

Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico

Goldgroup highlights its two producing underground mines, established processing infrastructure and extensive exploration land package across the Don David Gold Complex in Mexico.

September 8, 2026

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Nutriband has received a USPTO Notice of Publication for commercial brand name trademarks covering its lead abuse-deterrent fentanyl transdermal system, advancing its intellectual property and commercialization strategy as the Company prepares for future FDA and international regulatory review.

September 4, 2026

NextBoat Strengthens Board and Revenue Leadership to Power Its Next Phase of Growth

NextBoat has strengthened its leadership team with the appointment of Zebulon Hadley to its Board of Directors and Todd Bates as VP of Finance & Insurance, adding decades of combined experience in business scaling, governance and marine retail F&I as the Company enters its next phase of growth.

September 3, 2026

Cosmos Health: A Company Transformed — 2026 Year-to-Date

Cosmos Health provides a comprehensive 2026 year-to-date update highlighting three consecutive record revenue periods, the early retirement of its $8 million ATW convertible note, more than 5.1 million shares repurchased, global proprietary-brand expansion, U.S. launches, international patent filings and reaffirmed 2026–2029 financial guidance.

September 1, 2026

AEye’s Apollo™ Lidar Selected by Lunar Outpost for Pegasus Lunar Terrain Vehicle, Opening a New Market Category in Space Mobility

AEye’s Apollo™ long-range lidar has been selected by Lunar Outpost for integration onto the Pegasus Lunar Terrain Vehicle, marking a multi-million-dollar commercial engagement and AEye’s entry into the emerging space mobility market supporting NASA’s Artemis lunar program.

August 28, 2026

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

Cosmos Health has retired its $8 million senior secured ATW convertible note one year ahead of maturity, eliminating further dilution from conversions while reducing operating cash requirements, simplifying its capital structure and continuing its $5 million share repurchase program.

August 18, 2026

TruGolf to Acquire Polymath Research Inc., Bringing Tokenization Innovator to the Public Markets on Nasdaq

TruGolf Holdings has agreed to acquire Polymath Research Inc., bringing the developer of the institutional-grade Polymesh Layer-1 blockchain to the Nasdaq public markets and expanding TruGolf into regulated digital-asset tokenization infrastructure.

July 30, 2026

ZenaTech’s DaaS Oil and Gas Business Enters Strengthened Market With Higher Oil Prices and More Than US$500 Billion in Expected Canadian Energy Investment

ZenaTech says its newly acquired Velocity Geomatics business is entering a stronger Western Canadian energy market supported by higher oil prices and more than US$500 billion in expected industry investment over the next decade.

July 28, 2026

ZenaTech’s ZenaDrone Begins Testing Phase for Interceptor P-1 Counter-UAS Drone Platform

ZenaTech’s ZenaDrone has begun flight testing its low-cost Interceptor P-1 autonomous counter-UAS platform, advancing the company’s integrated defense system for intercepting hostile drones and coordinated drone swarms.

July 13, 2026

Oncolytics Biotech Reports FDA Milestone and Strong Clinical Progress in RAS-Mutant MSS Colorectal Cancer Trial

Oncolytics Biotech is preparing for an FDA Type D meeting to discuss a potential registrational pathway for pelareorep while rapidly activating clinical sites for its randomized REO 033 colorectal cancer trial.

June 22, 2026

Eva Live Targets Cybersecurity Aggressively, Standing Up an Internal Task Force to Meet AI Industry Needs

Through its Eva Defense subsidiary, Eva Live is forming a dedicated internal cybersecurity task force to move hard and fast on acquisitions and partnerships.

June 16, 2026

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech announced that the United States Patent and Trademark Office has issued a new patent broadly protecting the Company's proprietary manufacturing process for pelareorep, expected to provide intellectual property protection into 2044.

June 12, 2026

Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit

Cosmos Health reported that its C-Scrub and C-Sept antiseptic brands have generated over $1.5 million in combined annualized sales across the UK and Greece, with plans to expand across the EU targeting $7.4 million in annual revenue and $5.3 million in gross profit within three years.

June 11, 2026

Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance

Cosmos Health announced that it has been granted an additional 180-day period, through December 7, 2026, to regain compliance with the Nasdaq minimum bid price requirement.

June 05, 2026

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Cosmos Health announced the U.S. launch of Oliv18, expanding its 18 Series nutraceutical platform into cardiovascular and antioxidant categories with a USDA and EU organic certified, 100% solvent-free, whole olive polyphenol formulation from the Moroccan Saharan desert.

June 04, 2026

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

Cosmos Health announced that 96 Sky Premium Life products are now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand’s international distribution footprint and consumer accessibility across Europe.

June 04, 2026

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health identified approximately $20 million in non-core assets available for monetization, including real estate, digital assets, marketable securities, and other liquid assets, with potential proceeds to fund acquisitions, reduce debt, and unlock shareholder value.

June 02, 2026

Greenland Mines Appoints WSP Denmark to Continue Environmental Baseline Work at the Sarfartoq Rare Earth Project

Greenland Mines appointed WSP Denmark to continue environmental baseline work at the Sarfartoq rare earth project in southwest Greenland, advancing second-year environmental studies ahead of a future Environmental Impact Assessment.

June 02, 2026

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline

Cosmos Health provided a balance sheet update highlighting European Investment Bank financing discussions for up to €25 million, the expiration of Series B Warrants with no dilution, strengthening equity, real estate asset value, and reaffirmed long-term growth guidance.

June 01, 2026

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Cosmos Health announced the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the company’s first entry into the animal health market following successful European veterinary disinfectant standards testing.

April 30, 2026

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics announced it successfully completed its End-of-Phase 2 meeting with the FDA and received guidance on key elements of a pivotal Phase 3 trial for CAD-1005 in heparin-induced thrombocytopenia.

April 16, 2026

Off The Hook Yachts Expands Into New Boat Sales With Sportsman And Phenom Brands, Powered By Unique Storage Ecosystem

Company expands into new boat sales with Sportsman and Phenom brands, leveraging a unique storage ecosystem to drive recurring revenue and long-term customer retention

April 09, 2026

Off The Hook Yachts Launches Global Broker Expansion Initiative, Introducing Scalable Five-Tier Growth Model

Company introduces a scalable five-tier broker model designed to accelerate global expansion, increase transaction activity, and empower brokers to build high-income businesses

April 06, 2026

Off The Hook Yachts Expands Northeast and Mid-Atlantic Presence with Two New Strategic Marina Offices

New locations in Rhode Island and New Jersey enhance regional market density, increase transaction flow, and support continued broker hiring

April 02, 2026

Off The Hook Yachts Signs Definitive Agreement to Acquire Bellhart Marine, Creating the Carolinas’ Premier Mega Service & Refit Platform

Off The Hook Yachts announced a definitive agreement to acquire Bellhart Marine Group and its affiliated entities, expanding its in-house marine service, refit, and reconditioning capabilities across a three-location platform in the Carolinas.

April 01, 2026

Off The Hook Highlights Post-IPO Execution and First Quarter 2026 Progress

Off The Hook YS Inc. announced a corporate update highlighting its operational momentum in the first quarter of 2026 following a record 2025, citing expanded inventory financing capacity, a larger broker network, infrastructure growth, and continued investment in its AI-powered marine marketplace platform.

March 30, 2026

Off The Hook Yachts Reports Fourth Quarter and Full-Year 2025 Financial and Operating Results

Off The Hook Yachts reported record 2025 revenue of $119.9 million, sold a record 426 boats, raised 2026 revenue guidance to $150 million-$155 million, and highlighted stronger liquidity following its November 2025 IPO.

March 16, 2026

Auddia Highlights LT350 as Resilient AI Infrastructure as Iran War Exposes Vulnerabilities in Centralized Hyperscale Datacenters

Auddia highlighted the strategic relevance of its LT350 distributed AI infrastructure platform following new institutional research indicating that hyperscale AI datacenters have become military targets in the Iran war and are now considered exposed infrastructure during geopolitical conflicts.

March 12, 2026

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

Cadrenal Therapeutics highlighted recent scientific findings showing the potential of its first-in-class 12-LOX inhibitor, CAD-1005, to target inflammatory consequences of obesity and Type 2 diabetes.

March 11, 2026

Auddia Announces Non-binding LOI with NYSE Listed Medical REIT to Deploy LT350 Solar-Integrated AI Micro-Datacenter Canopy

Auddia announced that LT350 signed a non-binding LOI with a NYSE listed medical REIT to host LT350’s first pilot solar-integrated AI micro-datacenter canopy, expected to be at a hospital property in the Dallas Fort Worth MSA.

March 09, 2026

Auddia Showcases Discovr Radio at 2026 SXSW with Live Demo Listening Events and Brand Activation within the Artist Lounge

AI-first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio, today announced its official brand activation for Discovr Radio at the 2026 South by Southwest® (SXSW®) Conference and Festivals.